Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) remains the only curative approach for Myelofibrosis (MF). Scarce information exists in the literature on the outcome and, indeed, management of those MF patients who relapse following transplant. We hereby report on the management and outcome of 202 patients who relapsed post allo-HSCT for MF.

Additional Metadata
Keywords Allogeneic stem cell transplant, Fibrosis, JAK inhibitors, Mylelofibrosis, Relapse
Persistent URL dx.doi.org/10.1111/bjh.15407, hdl.handle.net/1765/107304
Journal British Journal of Haematology
Rights no subscription
Citation
Mclornan, D.P. (Donal P.), Szydlo, R, Robin, M, van Biezen, A, Koster, L. (Linda), Blok, H.J.P. (Henrik J. P.), … Kröger, N. (2018). Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: A retrospective study by the Chroni Malignancies Working Party of EBMT. British Journal of Haematology. doi:10.1111/bjh.15407